MicroRNA (miRNA) Market by Type, End-user and Geography - Forecast and Analysis 2023-2027

MicroRNA (miRNA) Market Forecast 2023-2027

The microRNA (miRNA) market size is estimated to grow by USD 2.02 billion at a CAGR of 18.91% between 2022 and 2027. Significant scientific advances in miRNA approaches and the development of miRNA therapeutics have assisted pharmaceutical and biotechnologists in developing, designing, and modifying biological systems at the molecular level. miRNA therapeutics have extensive applications in pharmaceutical and biotechnology research activities, especially DNA damage response and recombinant proteins. Researchers at pharmaceutical and biotechnology companies have consistently focused on using miRNAs to inhibit translation and thereby reduce protein synthesis. This will drive the growth of miRNA research activity in the pharmaceutical and biotechnology sectors, boosting the growth of the market during the forecast period.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation 

This market report extensively covers market segmentation by type (consumables and instruments), end-user (Academic and government research institutes, Biotechnology and pharmaceutical companies, and CROs and clinical diagnostic centers ), and geography (North America, Europe, Asia, and Rest of World (ROW)).  Market forecasting report examines historical data from 2017 to 2021, besides analyzing the current market scenario.

By Type

The market share by the consumables segment will be significant during the forecast period. The consumables segment includes whole blood, serum, and plasma, used for miRNA detection, among others. This segment contributes notably to the growth of the microRNA (miRNA) market owing to the repeated purchase of a wide variety of consumables for different testing purposes. Various types of consumables have gained prominence in recent years due to their popularity for in vitro and academic diagnostics.

Get a glance at the market contribution of various segments View a PDF Sample

The consumables segment was valued at USD 425.52 million in 2017. End users continuously use consumables such as plasma, serum, and other consumables to perform tests and experiments. Advances in technological reaction buffers have allowed reagents and enzymes to be more stable and active for longer, which has enhanced the value of reverse transcriptase (RT) polymerase chain reaction (PCR). As a result, advancements in technology, increase in applications and repeat purchases of consumer goods will drive the demand for consumables, which in turn is expected to boost the growth of the consumables segment of the market during the forecast period. 

By End-User

The academic and government research institutions segment is expected to grow during the forecast period due to increased funding from government agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF). The research center collaborates with contract research organizations (CROs), national and international universities, and medical centers to conduct clinical research. Research organizations are very prevalent in developed countries. Research activities are sponsored by large companies and government agencies, which helps to improve R&D activities. Therefore, such research activities are expected to propel the growth of the academic and government research institutes segment, which in turn is expected to boost the growth of the market during the forecast period.

The biotechnology and pharmaceutical companies segment is mainly driven by the rising pharmaceutical and biotechnology industry, increasing R&D spending, raised research in molecular biology towards life science-based research, and growing demand for biopharmaceuticals. Market players are focused on investing in miRNA therapeutics, drug testing, high-throughput screening, and developing innovative drug delivery formulations. Heavy investment in R&D by biotechnology providers is also driving the growth of this segment. In addition, rising R&D spending, advances in pharmacogenomics, the trend toward self-diagnosis of disease, and the emergence of digital PCR techniques for cancer diagnostics are driving the use of PCR reagents and driving the growth of the segment during the forecast period.

By Region

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. This region has high potential for miRNAs due to the hundreds of clinical trials underway in the region, especially in the US, for the treatment of cancer, human immunodeficiency virus (HIV)/syndrome acquired immunodeficiency (AIDS), cardiovascular disease (CVD) and others. Cancer is a big problem for the region and causes a lot of loss of life.

Furthermore, the treatment options available to treat cancer have many side effects and a risk of cancer recurrence. This has paved the way for new, long-acting treatment options with minimal side effects. MiRNA therapy is the mainstay of these new forms of treatment. Therefore, the increasing incidence of cancer is expected to drive the growth of the regional market during the forecast period. 

Buy Now Full Report and Discover More

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Miltenyi Biotec B.V. and Co. KG: The company offers miRNA such as GeneChip miRNA 4.0 Array and Flashtag bundle, FlashTag Biotin HSR RNA labeling kits, and mirVana miRNA mimics.

• BioGenex Laboratories Inc.
• BioVendor Laboratorni medicina AS
• GeneCopoeia Inc.
• Genelinx International Inc
• HEIM BIOTEK
• Illumina Inc.
• InteRNA Technologies B.V.
• Merck KGaA
• NanoString Technologies Inc.
• New England Biolabs Inc.
• OriGene Technologies Inc
• PerkinElmer Inc.
• QIAGEN NV
• Quantabio
• Regulus Therapeutics Inc.
• SeqMatic LLC
• Takara Bio Inc.
• TAmiRNA GmbH
• Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics Customer Landscape

The market is witnessing significant advancements in miRNA diagnostics, propelled by groundbreaking research such as the Nature article on the Soybean genome. Clinical trials are underway to explore miRNA's potential in addressing healthcare needs, driving commercialization efforts. Key aspects like isolation & purification and miRNA cDNA synthesis are crucial for profiling and localization in disease diagnosis. Consumables for miRNA expression studies are in high demand, especially in cancer research, highlighting the market's focus on advancing clinical diagnostics and therapeutics. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

The increasing prevalence of neurological disorders is the key driver for the growth of the market. The number of patients with a variety of neurological disorders, including Alzheimer's disease, epilepsy, stroke, Parkinson's disease, and brain tumors, has increased dramatically across the globe. These neurological disorders develop due to various factors such as bacterial and viral infections, genetic factors, and lack of immune response. Further, miRNA diagnostics are undergoing rigorous clinical trials and commercialization efforts to meet healthcare needs, emphasizing advancements in isolation and purification techniques for enhanced diagnostic accuracy.

In addition, due to the increasing prevalence of neurological disorders, providers are focusing on therapies to treat neurological disorders. Further, miRNA cDNA synthesis and profiling techniques play a vital role in disease diagnosis and cancer research, facilitating miRNA expression studies and localization studies with specialized consumables. Factors such as the growing incidence and prevalence of various neurological disorders as well as the increasing need to treat these disorders to save patients' lives, will boost the growth of the market during the forecast period. 

Significant Market Trends

The increasing number of partnerships and collaborations among market players is the leading trend in the market. Market players are adopting business strategies such as partnerships and collaborations with end-users and medical device companies to improve distribution channels and update product portfolios. For example, in March 2023, Qiagen partnered with global pharmaceutical company Les Laboratories d'Enst to develop a companion diagnostic for drugs used to treat acute myeloid leukemia (AML).

Likewise, in June 2023, biopharmaceutical company Regulus Therapeutics collaborated with Harvard Brigham and Women's Hospital to develop miR-155 for the treatment of lateral muscle atrophy. Presented an update on a preclinical study evaluating a library of oligonucleotides designed to inhibit. Hence, such developments are expected to drive the growth of the market during the forecast period. 

Major Market Challenges

The high heterogeneity of methodologies associated with miRNA is a challenge that affects the growth of the market. One of the biggest challenges for miRNA players is the lack of consensus on miRNA quantification methods. Several studies have suggested the use of miRNAs as biological markers for acute coronary syndrome, coronary artery disease, heart failure, and other cardiovascular diseases. The research conducted also highlights the heterogeneity of the methods used by different research groups based on different matrices such as age, gender, and ethnicity.

In addition to biological biases introduced by the use of different matrices, technical biases associated with different isolation protocols are also often observed. Differences between these protocols often preferentially isolate EVs, platelets, and protein complexes, affecting the relative levels of circulating miRNAs and ultimately limiting the reproducibility of study results. Thus, such factors may impede the growth of the market during the forecast period when conducting clinical studies on microRNA-based cardiovascular disease biomarkers. 

Buy Now Full Report and Discover More

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Segment Overview

The market research and growth report forecasts market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Type Outlook 
  • Consumables
  • Instruments

• End-User Outlook 
  • Academic and government research institutes
  • Biotechnology and pharmaceutical companies
  • CROs and clinical diagnostic centers

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Brazil 
    • Australia
    • Argentina

Market Analyst Overview:

The market is at the forefront of innovation and new technologies, focusing on gene expression at the post-transcriptional level. It offers diverse product formulations and delivery methods while prioritizing sustainability practices. Through functional analysis and target prediction, it validates animal training data and plant-specific miRNA targets for clinical diagnostic tests. With a keen eye on data security and privacy, it safeguards customer data and essential data assets.

Additionally, the market offers DLP solutions and robust data protection practices to mitigate data-related risks such as mismanagement and noncompliance, ensuring scalable data protection measures aligned with financial limits and risk profiles. Further, effective data governance frameworks are essential for ensuring secure data transfers and allocating funds and resources for robust data protection efforts, including stringent security policies and validation measures, particularly critical in the differentiation of cancer subtypes and addressing infectious diseases.

Market Scope
Report Coverage	Details
Page number	159
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 18.91%
Market growth 2023-2027	USD 2.02 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	17.41
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 45%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	BioGenex Laboratories Inc., BioVendor Laboratorni medicina AS, GeneCopoeia Inc., Genelinx International Inc., HEIM BIOTEK, Illumina Inc., InteRNA Technologies B.V., Merck KGaA, NanoString Technologies Inc., New England Biolabs Inc., OriGene Technologies Inc., PerkinElmer Inc., QIAGEN NV, Quantabio, Regulus Therapeutics Inc., SeqMatic LLC, Takara Bio Inc., TAmiRNA GmbH, Thermo Fisher Scientific Inc., and Miltenyi Biotec B.V. and Co. KG
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch